RALEIGH, N.C.(BUSINESS WIRE)Nov. 10, 1997

THC Metabolite A Promising New AntiInflammatory

Robert B. Zurier, MD, To Present Findings At American College of
Rheumatology Conference, Nov. 10

Atlantic Pharmaceuticals, Inc. (Nasdaq SmallCap: ATLC) announced today that
its proprietary lead compound CT3 has shown antiinflammatory activity in
preclinical animal studies that modeled the effects of arthritis. CT3 is a
nonpsychoactive synthetic derivative of a metabolite of
tetrahydrocannabinol (THC), a psychoactive compound found in cannabis
(marijuana). The study was led by University of Massachusetts Professor of
Medicine Robert B. Zurier, MD, who will report his findings today at the
61st National Scientific Meeting of the American College of Rheumatology in
Washington, D.C.

In several studies, oral administration of CT3 was found to have a potent
effect in reducing inflammation in laboratory animals. "Together with
CT3's previously demonstrated painrelieving action, these findings suggest
that CT3 could ultimately be a very useful drug if these therapeutic
effects can be replicated in future human clinical trials," stated J. D.
Lindjord, President and Chief Executive Officer of Atlantic
Pharmaceuticals.

Dr. Zurier is Director of the Division of Rheumatology at the University of
Massachusetts Medical Center, Worcester, and a member of Atlantic
Pharmaceuticals' Scientific Advisory Board. Dr. Zurier conducted the CT3
study in association with Ronald G. Rossetti, MPH, Joan H. Lane, DVM, DACVP,
John M. Goldberg, BA, Sheila A. Hunter, MSc, and Sumner H. Burstein, PhD,
all of the University of Massachusetts Medical Center.

CT3 is Atlantic Pharmaceuticals' internal name for dimethylheptylTHC11
oic acid (DMH11C), a synthetic drug that appears to reverse the
psychoactive effects of THC, while demonstrating unexpectedly powerful
analgesic and antiinflammatory properties. The Company is now conducting a
series of preclinical toxicology studies to test the safety of CT3 for
future testing in human clinical trials. The Company anticipates that these
studies will culminate with the filing of an investigational new drug (IND)
application with the U.S. Food and Drug Administration and other major
regulatory agencies.

Atlantic Pharmaceuticals is a biopharmaceutical company developing
pharmaceutical and biomedical products for a variety of therapeutic areas.
The Company's strategy, which differentiates its approach from most
biotechnology firms, is to develop a diverse portfolio of promising and
independent product candidates licensed from a variety of sources.
Currently, Atlantic is developing novel technologies in antisense gene
therapy, cataract removal, prevention of restenosis following coronary
angioplasty, and antiinflammatory/analgesic drugs.

This press release contains certain forwardlooking statements that relate
to future business and financial performance. Such statements can only be
predictions and are subject to a number of factors and uncertainties, which
may cause the actual events or future results to differ from those discussed
herein. Such factors include those risks described in the Company's most
recent reports on Forms 10QSB and 10KSB previously filed by Atlantic with
the Securities and Exchange Commission. The Company assumes no obligation
to update the information in this release. 0

For more information on Atlantic Pharmaceuticals' technologies, visit the
Company's homepage at http://www.atlan.com. Atlantic's press releases are
available through Business Wire's web site at http://www.businesswire.com.
The releases also are available at no charge through Business Wire's
faxondemand service at 8882868109.